the future of regenerative healing

We are a San Diego-based biotech company that discovered and named the "SMS" human stem cell and are utilizing our patented platform to develop treatments for horrible diseases like COPD.

What are Small Mobile Stem (SMS) cells?

They are a special type of stem cell that is found natively in our human blood.

Ethically obtained from adult human blood

Just two blood vials from one donor will generate trillions of SMS cells that can be applied to many patients.

Extensively safety tested

Both in-vitro and in-vivo testing in multiple animal species show no cellular toxicity or tumour generation.

Massive regenerative performance

SMS cells stimulate regenerative cell growth and show rapid tissue healing in testing.

Why are they so special?

Because SMS cells are better in EVERY way than current alternatives.

Non-Immunogenic Anti-inflammatory Multi-targeting Small and fast Easy to administer

How much better?

Mainstream stem cells need to be used within 72hrs to get maximum benefit. SMS cells maintain almost 100% potency at 30 days. This allows them to be transported and stored more efficiently with greater therapeutic effect.

Lifespan & Viability at Standard Refrigeration 2-8°C

All of these advantages make SMS cells far superior to currently available options.

Reserve Now

Creating a path to CURE

Chronic Obstructive Pulmonary Disease

There are 400M active COPD patients worldwide with approximately 3M deaths per year. It was thought to be incurable or irreversible UNTIL NOW.

Administer via NEBULIZER

We are the only technology able to achieve this as no other cells are hearty enough to survive.

Stimulates REGENERATION

SMS cells stimulate growth in lung cells, blood vessel formation, and can regenerate the air sacs.

Complete RECOVERY

In our animal studies we saw animal lungs make a complete recovery.

SMS cells DO what NO OTHER treatment can.

Which is why we built a platform.

Our platform is actively producing cell treatments in the areas of COPD and Orthopedics. These treatments are currently limited to use in research and ongoing clinical trials on paths to global commercialization.

Future project areas include:

Neurologic Cardiovascular Organ Disease Oral & Dental Cancer Therapy Cell & Tissue Engineering Longevity

and many more...

Investment Offer Details

Share Price

Round Size

Minimum Investment

Eligibility

$29

$20M

$400

All Investors

Now, there’s a limited-time opportunity for you to join us and help change the meaning of healing.

Reserve Your Investment Now

The Journey So Far

Animal safety studies – completed Q4 ’23 Product development – completed Q4 ’23

Compassionate Use application already filed in US/Internationally with focus on COPD patients

Current Roadmap of Clinical Trials

Ongoing, expected to be completed in Q2 2026

Expected to begin in Q2 2026 and complete in Q1 2027

Expected to begin in Q1 2027 and complete in Q4 2027

The Future - Ramping Up Production

We are already producing SMS cells and currently have $8M worth of inventory. This year we are adding the first of many planned new manufacturing facilities.

Each new facility will allow us to:

More Efficiently Produce Cells

Each new facility will allow us to greatly increase production of cells at more efficient cost.

Generate up to $25M/yr in Revenue per Facility

Every new facility will have modest operating costs that allow us to sell treatments at an estimated 80% + margin.

Get Ahead of Increased Demand

We anticipate increased demand from compassionate use applications, so our ability to produce and store SMS cells now ensures we can meet that demand.

Reserve Now

These expansions will allow us to serve a huge global market.

Meet Our Amazing Team

Abdulkader Rahmo, PhD

Co-founder, President, Chief Scientific Officer

Bachelors in biochemistry from the Swiss Federal Institute of Technology in Zurich; Ph.D. in Biochemistry from the University of Southern California in Los Angeles. Associate professor, with +30 years of experience in basic and applied research; 12 years primarily focused on SMS cell discovery and development. Experienced in clinical laboratory medicine. Cofounded and lead several private and public entities including the National Commission for Biotechnology. Member of the Board of Directors at California Medical Innovations Institute.

Ghassan Kassab, PhD

Board Member

Founder/President/CSO of California Medical Innovations Institute in San Diego, Founder of 3DT Holdings (incubator/accelerator of medical devices), and Founder of Acculab Lifesciences. Former professor (in Biomedical Engineering, Surgery, Cellular & Integrative Physiology) at Purdue University. Published over 700 publications and has over 250 issued or pending patents. He sold a major technology and sold four exclusive licenses to the major medical device industry. Board of director member for SMSbiotech.

Harry Friedman

CFO, Board of Directors Member at SMSbiotech

Seasoned Businessman, Investor, and Consultant. Experienced Board Member. Self-financed a high-growth technology company that successfully sold, 20-plus years later, to a large conglomerate. Started and participated in growing and selling several technology companies. Was a long-time member of Tech Coast Angels.

Roger Schechter, MD

Clinical Research Director at SMSbiotech

FACEP, FCCWS, UHM-ABEM, Medical Director for Wound Management at Palomar Health San Diego, Chief Medical Officer at Synergy Wound Technology, trained in Emergency Medicine, practices full time as a Wound Care and Hyperbaric Medicine Physician, a national level speaker on wound care, advanced wound care modalities, and non-invasive vascular testing.

Jason Kirkness, Ph.D.

Global Clinical Program Lead – Respiratory at SMSbiotech

A globally recognized medical science executive and pulmonary physiologist with extensive expertise in clinical research, medical device development, and innovation in respiratory medicine. He serves as Chairman of Drug Device Discovery and Development at the American Thoracic Society (ATS), Board of Directors for the ATS and is a member of the RIS Organizing Committee. Previously, he held senior roles at 4DMedical and Fisher & Paykel Healthcare. Has led over 100 clinical trials, secured significant funding from NIH and NHMRC, and authored over 50 high-impact publications. He is an Adjunct Associate Professor at the University of Miami and a former faculty member at Johns Hopkins.

David Schmitt, DVM

Veterinary Clinical Research Director at SMSbiotech

A Life Member of the Iowa Veterinary Medical Association (IVMA) with +40 years of service, retired as the Iowa State Veterinarian in 2019 after a distinguished career in both private practice and public service. Served as the State Veterinarian for IDALS, was a key figure in veterinary legislation, has received numerous honors, including Veterinarian of the Year by the IVMA. Served as President of the United States Animal Health Association.

Prof. Peter Wagner, MD

Board of Advisors Member at SMSbiotech

Emeritus Prof. at UCSD, leader in Respiratory Physiology, served as the Pres. of the American Thoracic Society, Pres. of the American Physiological Society, and Division Chief of both Physiology and Pulmonary Critical Care at UCSD School of Medicine, and as both member and chair of National Institutes of Health study sections.

Joe Kiani

Board of Directors Member at SMSbiotech

Cofounder of Masimo Corporation; Employing more than 4,250 people worldwide. Kiani and Masimo have more than 595 issued and 310 pending patents worldwide.

Gary Sieck, Ph.D.

Advisor at SMSbiotech

Prof. of Physiology at Mayo Clinic School of Medicine and Science. Studies focus on cell signaling mechanisms that underlie muscle performance, with a focus on regenerative processes that can improve acute and chronic disease conditions. He has published over 380 peer-reviewed papers and received multiple NIH grants over 37+ years.

Prof. James Sherley, MD

Board of Advisors Member at SMSbiotech

Former Associate professor at MIT (nine years), founder and former director of the Adult Stem Cell Technology Center at the Boston Biomedical Research Institute (5yrs); currently SMSbiotech board of advisor member, founder, and Director of Asymmetrex, LLC, Adjunct Associate Professor, Hematology-Oncology Department, Rhode Island Hospital Brown University.

Updates

October 08

New Japanese Patent Strengthens SMSbiotech’s Leadership in Regenerative Medicine

We are excited to announce that SMSbiotech has been granted a new Japanese patent for our innovative stem cell technology:

Japanese Patent No. 7,717,712 — “Stem Cell Compositions and Methods of Repairing Tissue”

Granted on July 25, 2025

This newly issued patent expands and strengthens SMSbiotech’s worldwide patent portfolio, further reinforcing our global leadership in regenerative medicine. It builds on our growing intellectual property foundation supporting the bio-manufacturing and therapeutic use of SMS cells for tissue repair and regeneration.

This milestone underscores SMSbiotech’s continued progress toward democratizing the application of adult stem cell technologies for human health.

October 01

Dr. Rahmo Showcases SMSbiotech’s Breakthrough Cell Therapy at Biotech Global Summit.

SMSbiotech is proud to announce that President and Chief Scientific Officer, Dr. Abdulkader Rahmo, presented our pioneering research at the Annual Global Summit on Public Health and Healthcare Systems (AGSPHHCS 2025). The conference took place in Bern, Switzerland, with Dr. Rahmo delivering his presentation virtually on September 19, 2025.

His talk, titled “Small Mobile Stem (SMS) Cells Potential Contribution to Treatments of Chronic Diseases” highlighted how SMSbiotech’s proprietary SMS cell platform addresses major limitations of conventional cell therapy and holds the potential to transform regenerative medicine.

Key Takeaways Included:

Industrial-Scale Production – SMS cells can be expanded extensively (over 27 passages) while maintaining potency and functionality.
Targeted Action – SMS cells exhibit a high binding affinity for repair-related target cells, supporting more precise and consistent clinical outcomes.
A Paradigm Shift – These breakthroughs pave the way for scalable, stable, and potent “off-the-shelf” (allogeneic) therapies designed for broad clinical application.

This platform is currently being evaluated in a Phase 1 clinical trial for Chronic Obstructive Pulmonary Disease (COPD)—a debilitating condition with no known cure.

We are honored to share this milestone with the global health community and remain deeply grateful for your continued support.

September 24

SMSbiotech Welcomes New Advisor Steven N. Copp, MD

SMSbiotech is proud to welcome Steven N. Copp, MD, Chair of the Department of Orthopedic Surgery at Scripps Clinic Medical Group and the Scripps Medical Foundation, as a valued advisor and collaborator.

This collaboration represents an important step in SMSbiotech’s mission to advance breakthrough therapies. Following the success of its first-in-human clinical trial in COPD, SMSbiotech is now preparing to initiate a new program focused on orthopedic joint conditions, including osteoarthritis.

Encouraged by outstanding results from the treatment of clinical animal cases in joint disease, SMSbiotech is building strong momentum toward human applications in orthopedics, strengthened by the expertise of its clinical collaborators.

Newest Advisor & Collaborator
Steven N. Copp, MD

Chair of the Department of Orthopedic Surgery at Scripps Clinic Medical Group and the Scripps Medical Foundation

September 17

Milestone Achievement – First COPD Patient Dosed in Phase 1 Trial

We are pleased to share a historic milestone in regenerative medicine. On July 11, 2025, at Veritus Research in Melbourne, Australia, we administered the first dose of our Small Mobile Stem (SMS) cell therapy to a patient in our Phase 1 human clinical trial for Chronic Obstructive Pulmonary Disease (COPD).

This marks the first time our groundbreaking regenerative therapy has been delivered to a human patient—transitioning years of research into clinical reality.

About the Trial

Title: A study to investigate Small Mobile Stem Cells (SMS cells) in participants aged 39–69 years with COPD
Participants: 18 patients
Objective: Evaluate safety and preliminary efficacy
Delivery Method: Simple nebulizer for direct lung delivery
Duration: Approximately 15 months

Our SMS cells are bio-manufactured at SMSbiotech and are designed to regenerate damaged lungs and other tissues. Preclinical studies have shown the potential to restore healthy lung function in animals in as little as 10 days.

Regulatory Approval

The trial is authorized by the Therapeutic Goods Administration (TGA), Australia’s regulatory body, comparable to the U.S. FDA.

A Message from Our President

“This is a profound moment for SMSbiotech and for millions living with COPD. We are optimistic about the potential of our therapy to fundamentally change the course of this disease.”
— Dr. Abdulkader Rahmo, President of SMSbiotech

This milestone strengthens our position in the global regenerative medicine market and supports our long-term strategy to deliver shareholder value through the development of innovative therapies. SMSbiotech will be increasing the dollar value of the stock price based on this crucial milestone.

We believe this achievement will generate heightened interest in SMSbiotech from both the scientific and investment communities.

We are also exploring applications for compassionate use once safety data becomes available, and evaluating potential indications in orthopedics based on very promising animal and in vitro studies.

Comments

THE [OFFERING MATERIALS] MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

THE COMPANY IS “TESTING THE WATERS” UNDER REGULATION A UNDER THE SECURITIES ACT OF 1933. THIS PROCESS ALLOWS COMPANIES TO DETERMINE WHETHER THERE MAY BE INTEREST IN AN EVENTUAL OFFERING OF ITS SECURITIES. THE COMPANY IS NOT UNDER ANY OBLIGATION TO MAKE AN OFFERING UNDER REGULATION A. IT MAY CHOOSE TO MAKE AN OFFERING TO SOME, BUT NOT ALL, OF THE PEOPLE WHO INDICATE AN INTEREST IN INVESTING, AND THAT OFFERING MIGHT NOT BE MADE UNDER REGULATION A. IF THE COMPANY DOES GO AHEAD WITH AN OFFERING, IT WILL ONLY BE ABLE TO MAKE SALES AFTER IT HAS FILED AN OFFERING STATEMENT WITH THE SECURITIES AND EXCHANGE COMMISSION (SEC) AND THE SEC HAS “QUALIFIED” THE OFFERING STATEMENT. THE INFORMATION IN THAT OFFERING STATEMENT WILL BE MORE COMPLETE THAN THE INFORMATION THE COMPANY IS PROVIDING NOW, AND COULD DIFFER IN IMPORTANT WAYS. YOU MUST READ THE DOCUMENTS FILED WITH THE SEC BEFORE INVESTING.

Manhattan Street Capital is compensated by SMSBiotech, Inc. for project management $10,000 per month listing the offering of the issuer’s securities $4,000 per month (charged as one payment for multiple offerings), and technology administration ($250 per investment by individuals, $1000 per investment for IRAs, Trusts or by US companies, LLCs or LPs, and $5000 per investment for professional investment entities. Payment is made in cash and a matching warrant. MSC might earn up to an estimated maximum amount of $472,584 on this offering.

You are here

SMSbiotech - Reg A